TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.

Sun Y, Maggs L, Panda A, Wright SJ, Cicerchia AM, Jenney A, Perricone MD, Mills CE, Cattaneo G, Ventin M, Chen F, Rasmussen MQ, Miranda A, Revach OY, Fang J, Fu A, Bowling PJ, Sharova T, Lawless A, Sorger PK, Bardeesy N, Wang X, Flaherty KT, Boland GM, Mehta A, Sade-Feldman M, Ferrone CR, Jenkins RW

Open source

DOI: 10.1158/2326-6066.cir-23-1011
Published: 2025 Feb 3
Container: Cancer immunology research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2326-6066.cir-23-1011,
  title = {TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.},
  author = {Sun Y and Maggs L and Panda A and Wright SJ and Cicerchia AM and Jenney A and Perricone MD and Mills CE and Cattaneo G and Ventin M and Chen F and Rasmussen MQ and Miranda A and Revach OY and Fang J and Fu A and Bowling PJ and Sharova T and Lawless A and Sorger PK and Bardeesy N and Wang X and Flaherty KT and Boland GM and Mehta A and Sade-Feldman M and Ferrone CR and Jenkins RW},
  year = {2025},
  journal = {Cancer immunology research},
  doi = {10.1158/2326-6066.cir-23-1011},
  url = {https://doi.org/10.1158/2326-6066.cir-23-1011}
}

RIS

TY  - JOUR
TI  - TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.
AU  - Sun Y
AU  - Maggs L
AU  - Panda A
AU  - Wright SJ
AU  - Cicerchia AM
AU  - Jenney A
AU  - Perricone MD
AU  - Mills CE
AU  - Cattaneo G
AU  - Ventin M
AU  - Chen F
AU  - Rasmussen MQ
AU  - Miranda A
AU  - Revach OY
AU  - Fang J
AU  - Fu A
AU  - Bowling PJ
AU  - Sharova T
AU  - Lawless A
AU  - Sorger PK
AU  - Bardeesy N
AU  - Wang X
AU  - Flaherty KT
AU  - Boland GM
AU  - Mehta A
AU  - Sade-Feldman M
AU  - Ferrone CR
AU  - Jenkins RW
PY  - 2025
JO  - Cancer immunology research
DO  - 10.1158/2326-6066.cir-23-1011
UR  - https://doi.org/10.1158/2326-6066.cir-23-1011
ER  -

APA

Y, S., L, M., A, P., SJ, W., AM, C., A, J., MD, P., CE, M., G, C., M, V., F, C., MQ, R., A, M., OY, R., J, F., A, F., PJ, B., T, S., A, L., PK, S., N, B., X, W., KT, F., GM, B., A, M., M, S., CR, F., & RW, J. (2025). TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.. Cancer immunology research. https://doi.org/10.1158/2326-6066.cir-23-1011

Source records

pubmed · retrieved 2026-09-26T12:37:19.114Z